Steve Pakola Regenxbio Inc. (RGNX) insider trading activity

Steve Pakola is Chief Medical Officer of REGENXBIO Inc.. Currently has a direct ownership of 258,317 shares of RGNX, which is worth approximately $2.97 Million. The most recent transaction as insider was on Jan 06, 2026, when has been sold 65,847 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 258K

22.59% 3M change

70.3% 12M change

Total Value Held $2.97 Million

STEVE PAKOLA Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 06 2026	BUY Grant, award, or other acquisition	-	65,847 Added 20.31%	258,317 Common Stock
Jan 02 2026	SELL Payment of exercise price or tax liability	$262,756 $14.4 p/Share	18,247 Reduced 8.66%	192,470 Common Stock
Feb 01 2025	SELL Payment of exercise price or tax liability	$42,472 $8.07 p/Share	5,263 Reduced 2.44%	210,717 Common Stock
Jan 02 2025	SELL Payment of exercise price or tax liability	$107,377 $7.73 p/Share	13,891 Reduced 8.39%	151,687 Common Stock
Jan 02 2025	BUY Grant, award, or other acquisition	-	64,293 Added 22.94%	215,980 Common Stock
Aug 01 2024	BUY Grant, award, or other acquisition	-	58,386 Added 26.07%	165,578 Common Stock
Mar 05 2024	SELL Open market or private sale	$365,220 $28.36 p/Share	12,878 Reduced 10.73%	107,192 Common Stock

Mar 05 2024	BUY Exercise of conversion of derivative security	$286,535 $22.25 p/Share	12,878 Added 9.69%	120,070 Common Stock
Jan 03 2024	SELL Open market or private sale	$299,751 $17.39 p/Share	17,237 Reduced 13.85%	107,192 Common Stock
Jan 02 2024	SELL Payment of exercise price or tax liability	$186,410 $17.95 p/Share	10,385 Reduced 10.11%	92,378 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	32,051 Added 20.48%	124,429 Common Stock
Jan 03 2023	SELL Open market or private sale	$69,569 $22.17 p/Share	3,138 Reduced 20.49%	12,175 Common Stock
Jan 03 2023	SELL Payment of exercise price or tax liability	$41,663 $22.68 p/Share	1,837 Reduced 10.71%	15,313 Common Stock
Jan 03 2023	BUY Grant, award, or other acquisition	-	90,588 Added 46.85%	102,763 Common Stock
Jan 03 2022	SELL Open market or private sale	$53,932 $33.75 p/Share	1,598 Reduced 16.23%	8,250 Common Stock
Jan 03 2022	BUY Grant, award, or other acquisition	-	8,900 Added 34.17%	17,150 Common Stock
Jan 01 2022	SELL Payment of exercise price or tax liability	$37,670 $32.7 p/Share	1,152 Reduced 10.47%	9,848 Common Stock
Jan 04 2021	BUY Grant, award, or other acquisition	-	11,000 Added 50.0%	11,000 Common Stock

Steve Pakola

Chief Medical Officer

Rockville, MD

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RGNX shares.

Notify only if

Value

Insider Trading

Get notified when an Regenxbio Inc. insider buys or sells RGNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to REGENXBIO Inc.

Track Activities on RGNX

Account